Direct-acting antivirals for chronic hepatitis C.

@article{Jakobsen2017DirectactingAF,
  title={Direct-acting antivirals for chronic hepatitis C.},
  author={Janus Christian Jakobsen and Emil Eik Nielsen and Joshua Feinberg and Kiran Kumar Katakam and Kristina Fobian and Goran Hauser and Goran Poropat and Snezana Djurisic and Karl Heinz Weiss and Milica Bjelakovic and Goran B Bjelakovic and Sarah Louise Klingenberg and Jian-Ping Liu and Dimitrinka Nikolova and Ronald L Koretz and Christian N Gluud},
  journal={The Cochrane database of systematic reviews},
  year={2017},
  volume={9},
  pages={
          CD012143
        }
}
BACKGROUND Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs), e.g. sofosbuvir, are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). Sustained virological response (SVR) is used by investigators and regulatory agencies as a surrogate outcome for… CONTINUE READING